The effects of protein type and added leucine on post-exercise muscle protein synthesis

The effects of protein type and added leucine on post-exercise muscle protein synthesis - Protein type and leucine on post-exercise protein synthesis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON42133

Enrollment

Registered

2015-01-08

Start date

2015-03-19

Completion date

Unknown

Last updated

2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

muscle anabolism

Interventions

Randomized, double-blind, parallel group design in which subjects are randomly assigned to one of the 6 different nutrition treatment groups: carbohydrate (placebo), whey protein, casein protein, mi

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Male • Healthy and physically active (as determined by medical and activity questionnaire) • 20-30 years of age • Having given informed consent

Exclusion criteria

Exclusion criteria: • Having any identified metabolic or intestinal disorders • Tobacco use • Aspirin use in the 4 days prior to the experimental trial • Consumption of prescription medications or any performance enhancing agent • Inability to endure the strenuous exercise bouts e.g. injuries • Alcohol intake during the 48 hours prior to each of the testing days • Currently participating or having participated in another clinical trial during the last 4 weeks prior to the beginning of this study

Design outcomes

Primary

Measure	Time frame
The main study endpoint is the fractional synthetic rate (FSR) of muscle protein synthesis (mixed, myofibrillar, and mitochondrial proteins) from 0-6 hours in the post-prandial period.	—

Secondary

Measure	Time frame
Secondary endpoints include: • The fractional synthetic rate (FSR) of muscle protein synthesis (mixed, myofibrillar, and mitochondrial proteins) from 0-2 and 2-6 hours in the post-prandial period. • Plasma free phenylalanine enrichment (expressed as MPE) • Plasma free tyrosine enrichment (expressed as MPE) • Plasma total phenylalanine (expressed as µmol/L) • Plasma total tyrosine (expressed as µmol/L) • Total plasma amino acids (AAmax [µmol/L]) • Plasma glucose (glucosemax [mmol/L]) • Plasma insulin (insulinmax [mU/L])	—

Measure

Time frame

Secondary endpoints include: • The fractional synthetic rate (FSR) of muscle protein synthesis (mixed, myofibrillar, and mitochondrial proteins) from 0-2 and 2-6 hours in the post-prandial period. • Plasma free phenylalanine enrichment (expressed as MPE) • Plasma free tyrosine enrichment (expressed as MPE) • Plasma total phenylalanine (expressed as µmol/L) • Plasma total tyrosine (expressed as µmol/L) • Total plasma amino acids (AAmax [µmol/L]) • Plasma glucose (glucosemax [mmol/L]) • Plasma insulin (insulinmax [mU/L])

—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)